Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Obesity Surgery
Erschienen in: Obesity Surgery 8/2019

29.04.2019 | Original Contributions

Impact of Intragastric Balloon Treatment on Adipokines, Cytokines, and Metabolic Profile in Obese Individuals

verfasst von: Marcella Rodrigues Guedes, Ricardo José Fittipaldi-Fernandez, Cristina Fajardo Diestel, Márcia Regina Simas Torres Klein

Erschienen in: Obesity Surgery | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Obesity is accompanied by adipose tissue remodeling characterized by increased production of tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, leptin and resistin and reduced secretion of adiponectin, which favors inflammation, metabolic disorders, and cardiovascular diseases. Although intragastric balloon (IGB) can be considered safe and effective for weight loss, its effect on serum levels of these biomarkers has been evaluated only in a few studies, while no previous study evaluated its effect on circulating levels of resistin, TNF-α, and IL-6. The aim of this study was to evaluate the changes in serum levels of metabolic and inflammatory biomarkers in obese patients submitted to IGB treatment.

Methods

A prospective observational study involving 42 patients with obesity using IGB for 6 months. The patients were evaluated, on the day of insertion and withdrawal or adjustment of IGB, for the following: anthropometric measures and serum levels of adiponectin, leptin, resistin, TNF-α, IL-6, high-sensitivity C-reactive protein (hs-CRP), glucose, insulin, uric acid, triglycerides, and total cholesterol and fractions.

Results

The body mass index decreased from 35.15 ± 0.41 to 29.50 ± 0.54 kg/m2. There was a reduction (p < 0.05) in leptin, hs-CRP, glucose, insulin, HOMA-IR, and triglycerides, while the adiponectin/leptin ratio increased (p < 0.05). Moreover, weight loss presented (1) a positive association with the decrease in leptin, hs-CRP, glucose, insulin, HOMA-IR, uric acid, and total cholesterol and (2) a negative association with the reduction in adiponectin/leptin ratio.

Conclusions

The present study suggests that 6 months of IGB treatment in obese individuals reduce serum leptin and hs-CRP and improves insulin resistance and lipid profile which may decrease cardiovascular risk.
Literatur
1.
Kushner RF, Kahan S. Introduction: the state of obesity in 2017. Med Clin North Am. 2018;102(1):1–11.PubMed
2.
3.
Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016;387:1947–56.PubMed
4.
Bray GA, Kim KK, Wilding JPH, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–23.PubMed
5.
Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156.PubMedPubMedCentral
6.
The Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju SN, et al. Body-mass index and all-cause mortality: individual participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776–86.PubMedPubMedCentral
7.
Upadhyay J, Farr O, Perakakis N, et al. Obesity as a disease. Med Clin N Am. 2018;102:13–33.PubMed
8.
Fuster JJ, Ouchi N, Gokce N, et al. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res. 2016;118(11):1786–807.PubMedPubMedCentral
9.
Martyniak K, Masternak MM. Changes in adipose tissue cellular composition during obesity and aging as a cause of metabolic dysregulation. Exp Gerontol. 2017;94:59–63.PubMed
10.
Blüher M. Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance? Clin Sci. 2016;130(18):1603–14.PubMed
11.
Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis. Curr Opin Lipidol. 2017;28(4):347–54.PubMed
12.
Jensen MD, Ryan DH, Apovian CM, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023.PubMed
13.
Yumuk V, Tsigos C, Fried M, et al. Obesity management task force of the european association for the study of obesity. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402–24.PubMedPubMedCentral
14.
Ryan DH, Kahan S. Guideline recommendations for obesity management. Med Clin North Am. 2018;102(1):49–63.PubMed
15.
Ali MR, Moustarah F, Kim JJ. American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. American Society for Metabolic and Bariatric Surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons. Surg Obes Relat Dis. 2016;12(3):462–7.PubMed
16.
Neto MG, Silva LB, Grecco E, et al. Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2017;28.
17.
Popov VB, Ou A, Schulman AR, et al. The impact of intragastric balloons on obesity-related co-morbidities: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112(3):429–39.PubMed
18.
Alsabah S, Al Haddad E, Ekrouf S, et al. The safety and efficacy of the procedureless intragastric balloon. Surg Obes Relat Dis. 2018;14(3):311–7.PubMed
19.
Garcia L, Vajanaphanich S, Morton JM. Comorbidity remission following intragastric dual balloon placement. Obes Surg. 2018.
20.
Mion F, Napoléon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg. 2005;15(4):510–6.PubMed
21.
Konopko-Zubrzycka M, Baniukiewicz A, Wróblewski E, et al. The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obesity. J Clin Endocrinol Metab. 2009;94(5):1644–9.PubMed
22.
Sekino Y, Imajo K, Sakai E, et al. Time-course of changes of visceral fat area, liver volume and liver fat area during intragastric balloon therapy in Japanese super-obese patients. Intern Med. 2011;50(21):2449–55.PubMed
23.
Fuller NR, Lau NS, Denyer G, et al. An intragastric balloon produces large weight losses in the absence of a change in ghrelin or peptide YY. Clin Obes. 2013;3(6):172–9.PubMed
24.
Bužga M, Evžen M, Pavel K, et al. Effects of the intragastric balloon MedSil on weight loss, fat tissue, lipid metabolism, and hormones involved in energy balance. Obes Surg. 2014;24(6):909–15.PubMedPubMedCentral
25.
Joffe OY, Molnar IM, Tarasyuk TV, et al. Morphological changes of gastric mucosa after insertion of intragastric balloon. Klin Khir. 2015;10:70–2.
26.
Atef E, Zalata KR, Atef H, et al. Increased proliferative activity accompanies the local inflammatory response of gastric mucosa after intragastric balloon insertion. Dig Dis Sci. 2016;61(12):3498–505.PubMed
27.
28.
He Y, Lu L, Wei X, et al. The multimerization and secretion of adiponectin are regulated by TNF-alpha. Endocrine. 2016;51(3):456–68.PubMed
29.
30.
Fittipaldi-Fernandez RJ, Guedes MR, Galvao Neto MP, et al. Efficacy of intragastric balloon treatment for adolescent obesity. Obes Surg. 2017;27(10):2546–51.PubMed
31.
Tai CM, Lin HY, Yen YC, et al. Effectiveness of intragastric balloon treatment for obese patients: one-year follow-up after balloon removal. Obes Surg. 2013;23(12):2068–74.PubMed
32.
Ribeiro da Silva J, Proença L, Rodrigues A, et al. Intragastric balloon for obesity treatment: safety, tolerance, and efficacy. GE Port J Gastroenterol. 2018;25(5):236–42.PubMed
33.
WHO - World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. Geneva: WHO Techinical Report Series (894); 2000.
34.
35.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(60):499–502.PubMed
36.
Matthews DR, Hosker JR, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMed
37.
Geloneze B, Repetto EM, Geloneze SR, et al. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract. 2006;72(2):219–20.PubMed
38.
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American College Of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87.PubMed
39.
Triantafyllou GA, Paschou SA, Mantzoros CS. Leptin and hormones: energy homeostasis. Endocrinol Metab Clin N Am. 2016;45(3):633–45.
40.
Pérez-Pérez A, Vilariño-García T, Fernández-Riejos P, et al. Role of leptin as a link between metabolism and the immune system. Cytokine Growth Factor Rev. 2017;35:71–84.PubMed
41.
Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36(7):461–70.PubMed
42.
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2018.
43.
Ho TP, Zhao X, Courville AB, et al. Effects of a 12-month moderate weight loss intervention on insulin sensitivity and inflammation status in nondiabetic overweight and obese subjects. Horm Metab Res. 2015;47(4):289–96.PubMed
44.
Belalcazar LM, Lang W, Haffner SM, et al. Improving adiponectin levels in individuals with diabetes and obesity: insights from look AHEAD. Diabetes Care. 2015;38(8):1544–50.PubMedPubMedCentral
45.
Lips MA, van Klinken JB, Pijl H, et al. Weight loss induced by very low calorie diet is associated with a more beneficial systemic inflammatory profile than by Roux-en-Y gastric bypass. Metabolism. 2016;65(11):1614–20.PubMed
46.
Illán-Gómez F, Gonzálvez-Ortega M, Orea-Soler I, et al. Obesity and inflammation: change in adiponectin, c-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22:950–5.PubMed
47.
Netto BD, Bettini SC, Clemente AP, et al. Roux-en-y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity. Obes Surg. 2015;25(6):1010–8.PubMed
48.
Coimbra S, Ferreira C, Belo L, et al. Impact of weight loss on inflammation and red blood cell biomarkers after laparoscopic gastric banding surgery. J Investig Med. 2017.
49.
Miller EG, Sethi P, Nowson CA, et al. Effects of progressive resistance training and weight loss versus weight loss alone on inflammatory and endothelial biomarkers in older adults with type 2 diabetes. Eur J Appl Physiol. 2017;117:1669–78.PubMed
50.
Yuntao B, Qinghua S. Macrophage recruitment in obese adipose tissue. Obes Rev. 2015;16(2):127–36.
51.
Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–9.PubMed
52.
Zand H, Morshedzadeh N, Naghashian F. Signaling pathways linking inflammation to insulin resistance. Diabetes Metab Syndr. 2017;11(Suppl 1):307–9.
53.
Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014;63(4):250–9.PubMed
54.
Arismendi E, Rivas E, Agustí A, et al. The systemic inflammome of severe obesity before and after bariatric surgery. PLoS One. 2014;9(9):e107859.PubMedPubMedCentral
55.
Freitas Jr WR, Oliveira LVF, Perez EA, et al. Systemic inflammation in severe obese patients undergoing surgery for obesity and weight-related diseases. Obes Surg. 2018;28(7):1931–42.PubMedPubMedCentral
56.
Illán-Gómez F, Ortega GM, Alonso AA, et al. Obesity, endothelial function and inflammation: the effects of weight loss after bariatric surgery. Nutr Hosp. 2016;33(6):1340–6.PubMed
57.
Ma W, Huang T, Zheng Y, et al. Weight-loss diets, adiponectin, and changes in cardiometabolic risk in the 2-year POUNDS lost trial. J Clin Endocrinol Metab. 2016;101(6):2415–22.PubMedPubMedCentral
58.
Albuquerque A, Sarmento JA, Azevedo RM, et al. Intra-gastric balloon leads to a proportional decrease between body mass index and serum C-reactive protein levels. J Gastroenterol Hepatol. 2013;28:495.
59.
Madeira E, Madeira M, Guedes EP, et al. Impact of weight loss with intragastric balloon on bone density and microstructure in obese adults. J Clin Densitom. 2018.
60.
Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med. 2007;167(1):31–9.PubMed
61.
Yatsuya H, Jeffery RW, Langer SL, et al. Changes in C-reactive protein during weight loss and the association with changes in anthropometric variables in men and women: LIFE Study. Int J Obes. 2011;35(5):684–91.
62.
Belalcazar LM, Reboussin DM, Haffner SM, et al. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010;33(11):2297–303.PubMedPubMedCentral
63.
Rość D, Adamczyk P, Boinska J, et al. CRP, but not TNF-α or IL-6, decreases after weight loss in patients with morbid obesity exposed to intensive weight reduction and balneological treatment. J Zhejiang Univ Sci B. 2015;16(5):404–11.PubMedPubMedCentral
64.
Pardina E, Ferrer R, Baena-Fustegueras JA, et al. Only C-reactive protein, but not TNF-α or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg. 2012;22(1):131–9.PubMed
65.
Li Y, Zhong X, Cheng G, et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. Atherosclerosis. 2017;259:75–82.PubMed
66.
Mallipedhi A, Sarah L, Prior SL, et al. Changes in inflammatory markers after sleeve gastrectomy in subjects with impaired glucose homeostasis and type 2 diabetes. Surg Obes Relat Dis. 2014;10(6):1123–8.PubMed
67.
Snel M, van Diepen JA, Stijnen T, et al. Immediate and long-term effects of addition of exercise to a 16-week very low calorie diet on low-grade inflammation in obese, insulin-dependent type 2 diabetic patients. Food Chem Toxicol. 2011;49(12):3104–11.PubMed
68.
Mafort TT, Madeira E, Madeira M, et al. Six-month intragastric balloon treatment for obesity improves lung function, body composition, and metabolic syndrome. Obes Surg. 2014;24(2):232–40.PubMed
Metadaten
Titel
Impact of Intragastric Balloon Treatment on Adipokines, Cytokines, and Metabolic Profile in Obese Individuals
verfasst von
Marcella Rodrigues Guedes
Ricardo José Fittipaldi-Fernandez
Cristina Fajardo Diestel
Márcia Regina Simas Torres Klein
Publikationsdatum
29.04.2019
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 8/2019
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-019-03891-8

Weitere Artikel der Ausgabe 8/2019

Obesity Surgery 8/2019 Zur Ausgabe

Original Contributions

Surgical Morbidity in the Elderly Bariatric Patient: Does Age Matter?

Original Contributions

Bowel Reconstruction to Treat Chronic Diarrhea and Hypoproteinemia Following Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy: a Single-Site Experience

Original Contributions

Serum Bile Acid Levels Before and After Sleeve Gastrectomy and Their Correlation with Obesity-Related Comorbidities

Correction

Correction to: Surgical Morbidity in the Elderly Bariatric Patient: Does Age Matter?

Brief Communication

Exploring the Effects of Telemedicine on Bariatric Surgery Follow-up: a Matched Case Control Study

Video Submission

Endoscopic Tunneled Stricturotomy with Full-Thickness Dissection in the Management of a Sleeve Gastrectomy Stenosis

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

10.04.2024 | Narbenhernie | Nachrichten

Deutlich weniger Narbenhernien mit der Small-Bites-Technik
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.